

SPH.L

Sinclair Pharma plc

Result of Annual General Meeting

18 November 2010, Godalming, UK: Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, is pleased to announce that at the Annual General Meeting of the Company held earlier today, the resolutions set out in the notice of annual general meeting posted with the Annual Report of the Company and dated 22 October 2010, were duly passed without amendment.

The resolutions were passed on a show of hands. A breakdown of the proxies lodged prior to the Annual General Meeting in respect of the resolutions is summarised below:

	<u>For</u>	<u>Against</u>	<u>Withheld</u>
Resolution 1	124,342,572	0	2,908,542
Resolution 2	124,192,572	3,058,542	0
Resolution 3	124,192,572	3,058,542	0
Resolution 4	127,101,114	150,000	0
Resolution 5	122,931,933	4,319,181	0
Resolution 6	127,076,114	160,000	15,000
Resolution 7	125,820,806	1,415,308	15,000
Resolution 8	124,333,589	2,915,216	2,309
Resolution 9	124,192,572	3,058,542	0

Notes:

1. Any proxy arrangements which gave discretion to the Chairman have been included in the "For" totals.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3. The total number of valid proxy appointments and associated voting instructions received prior to the Annual General Meeting was 127,251,114.
4. The share capital of Sinclair as at 18 November 2010 is 230,779,767 ordinary shares. This figure includes 301,579 ordinary shares allotted but not yet issued to employees of the Company pursuant to a share award scheme operated by the Company.

The results of the proxy votes lodged in advance of the Annual General Meeting will be available on Sinclair's website www.sinclairpharma.com shortly.

In accordance with Sinclair's obligations under Listing Rule 9.6.2, the full text of the resolutions passed as special business has been submitted to the National Storage Mechanism and will shortly be available for viewing at www.hemscott.com/nsm.do.

For further information please contact:

Sinclair Pharma plc
Chris Spooner, CEO
Alan Olby, CFO

Tel: +44 (0) 1483 410 600

Singer Capital Markets Ltd

Shaun Dobson

Claes Spång

Tel: +44 (0)20 3205 7500

Biddicks, Financial Public Relations

Shane Dolan

Tel: +44 (0)20 7448 1000

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed and emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.